CA2579313A1 - Pyrazole kinase modulators and methods of use as c-kit or fit-3 kinase inhibitors - Google Patents

Pyrazole kinase modulators and methods of use as c-kit or fit-3 kinase inhibitors Download PDF

Info

Publication number
CA2579313A1
CA2579313A1 CA002579313A CA2579313A CA2579313A1 CA 2579313 A1 CA2579313 A1 CA 2579313A1 CA 002579313 A CA002579313 A CA 002579313A CA 2579313 A CA2579313 A CA 2579313A CA 2579313 A1 CA2579313 A1 CA 2579313A1
Authority
CA
Canada
Prior art keywords
phenyl
pyrazol
optionally substituted
urea
methylpiperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002579313A
Other languages
English (en)
French (fr)
Inventor
Tae-Gon Baik
Chris A. Buhr
Sunghoon Ma
John M. Nuss
Zerom Tesfai
Longcheng Wang
Bryan K. S. Yeung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2579313A1 publication Critical patent/CA2579313A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA002579313A 2004-09-17 2005-09-15 Pyrazole kinase modulators and methods of use as c-kit or fit-3 kinase inhibitors Abandoned CA2579313A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61068904P 2004-09-17 2004-09-17
US60/610,689 2004-09-17
PCT/US2005/032839 WO2006033943A2 (en) 2004-09-17 2005-09-15 Pyrazole kinase modulators and methods of use

Publications (1)

Publication Number Publication Date
CA2579313A1 true CA2579313A1 (en) 2006-03-30

Family

ID=36090487

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002579313A Abandoned CA2579313A1 (en) 2004-09-17 2005-09-15 Pyrazole kinase modulators and methods of use as c-kit or fit-3 kinase inhibitors

Country Status (6)

Country Link
US (1) US8710038B2 (enExample)
EP (1) EP1797072A4 (enExample)
JP (2) JP5063351B2 (enExample)
AU (1) AU2005287170B2 (enExample)
CA (1) CA2579313A1 (enExample)
WO (1) WO2006033943A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR051093A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa desaturasa
MX2007003332A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
CN101058561B (zh) * 2006-04-19 2011-01-26 苏州爱斯鹏药物研发有限责任公司 用于抑制蛋白激酶的二苯脲衍生物及其组合物和用途
WO2009143039A2 (en) * 2008-05-19 2009-11-26 Schering Corporation Heterocyclic compounds as factor ixa inhibitors
ES2620027T3 (es) 2008-09-03 2017-06-27 Biomarin Pharmaceutical Inc. Composiciones que incluyen derivados del ácido 6-aminohexanoico como inhibidores de HDAC
US8329757B2 (en) * 2008-10-14 2012-12-11 Charlesson, Llc Curcumin analog compositions and related methods
EP2545046A4 (en) 2010-03-11 2015-03-25 Sumitomo Dainippon Pharma Co Ltd CYCLIC N-ACYL-AMINE DERIVATIVE OR PHARMACEUTICALLY ALLOWED SALT THEREOF
KR20130089232A (ko) * 2010-06-15 2013-08-09 바이엘 인텔렉쳐 프로퍼티 게엠베하 안트라닐산 디아미드 유도체
US9540395B2 (en) 2011-02-28 2017-01-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
CA2832650C (en) 2011-04-11 2019-05-07 Pharma Eight Co. Ltd. Pyrazole derivative
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
RU2682679C2 (ru) * 2012-10-10 2019-03-20 Грин Тек Ко., Лтд. Новые производные пиразола
PL403149A1 (pl) * 2013-03-14 2014-09-15 Celon Pharma Spółka Akcyjna Nowe związki pochodne pirazolilobenzo[d]imidazolu
KR20150132345A (ko) 2013-03-15 2015-11-25 바이오마린 파머수티컬 인크. Hdac 저해제
EP2944635B1 (en) * 2014-05-15 2018-11-28 Council of Scientific & Industrial Research Pyrazole linked benzimidazole conjugates and a process for preparation thereof
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
EP3643705A1 (en) * 2018-10-24 2020-04-29 Basf Se Pesticidal compounds
JP7742175B2 (ja) * 2021-03-03 2025-09-19 白鳥製薬株式会社 ピラゾール化合物の製造方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE923028C (de) 1952-04-02 1955-01-31 Basf Ag Verfahren zur Herstellung von Kuepenfarbstoffen
US3948937A (en) * 1972-02-29 1976-04-06 E. I. Du Pont De Nemours And Company Pyrazole plant growth regulants
ZA744908B (en) * 1973-09-17 1975-08-27 American Cyanamid Co Catalytic dehydrogenation process for the preparation of 3,5-disubstituted pyrazoles
GB1484615A (en) * 1974-11-23 1977-09-01 Lepetit Spa Tricyclic n-containing derivatives
US4014896A (en) * 1975-02-12 1977-03-29 American Cyanamid Company Catalytic dehydrogenation process for the preparation of 3,4,5-trisubstituted pyrazoles
IE59813B1 (en) * 1986-05-09 1994-04-06 Warner Lambert Co Styryl pyrazoles, isoxazoles and analogs thereof having activity as 5-lipoxy-genase inhibitors and pharmaceutical compositions containing them
US4877881A (en) * 1987-04-06 1989-10-31 Warner-Lambert Company Process of preparing pyrazoles, isoxazoles and analogs thereof having activity as 5-lipoxygenase inhibitors
DE3903993A1 (de) * 1989-02-10 1990-08-16 Basf Ag Diarylsubstituierte heterocyclische verbindungen, ihre herstellung und arzneimittel daraus
JPH04124178A (ja) * 1990-09-12 1992-04-24 Sds Biotech Kk 複素環式化合物および該化合物を含有する除草剤
DE59407859D1 (de) * 1993-06-08 1999-04-08 Basf Ag Verfahren zur Herstellung von N-substituierten Pyrazolen
US5783593A (en) * 1993-11-04 1998-07-21 Abbott Laboratories Inhibitors of squalene synthetase and protein farnesyltransferase
DE19500838A1 (de) * 1995-01-13 1996-07-18 Basf Ag Verfahren zur Herstellung von 3,5-Diarylpyrazolen
DE69935335T2 (de) 1998-08-07 2007-11-22 Novartis Vaccines and Diagnostics, Inc., Emeryville Pyrazole als modulatoren des östrogenrezeptors
AU1199600A (en) * 1998-10-02 2000-04-26 Board Of Trustees Of The University Of Illinois, The Estrogen receptor ligands
DE19904397A1 (de) 1999-02-04 2000-08-10 Bayer Ag Verwendung von Pyrazol-Carbonsäureamiden
JP2003523958A (ja) * 1999-12-23 2003-08-12 ニトロメド インコーポレーテッド ニトロソ化およびニトロシル化されたシクロオキシゲナーゼ−２の阻害剤、組成物ならびに使用法
US6914069B2 (en) * 2000-05-19 2005-07-05 Applied Research Systems Ars Holding N.V. Pharmaceutically active compounds and methods of use
SI1373263T1 (en) * 2001-04-05 2005-04-30 Torrent Pharmaceuticals Ltd Heterocyclic compounds for aging-related and diabetic vascular complications
CN1638776A (zh) 2001-06-08 2005-07-13 西托维亚公司 取代的3－芳基－5－芳基－[1,2,4]－噁二唑和类似物
IL161576A0 (en) 2001-10-26 2004-09-27 Aventis Pharma Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
FR2831536A1 (fr) * 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
JP2005162612A (ja) * 2002-01-09 2005-06-23 Ajinomoto Co Inc アシルスルホンアミド誘導体
US6790979B2 (en) * 2002-04-17 2004-09-14 University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
NI200300045A (es) * 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
AU2002314566A1 (en) * 2002-06-17 2003-12-31 Ho-Jeong Kwon Novel curcumin derivatives
US20050113423A1 (en) * 2003-03-12 2005-05-26 Vangoor Frederick F. Modulators of ATP-binding cassette transporters
US7115642B2 (en) * 2003-05-02 2006-10-03 Rigel Pharmaceuticals, Inc. Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating HCV infection
GB0326601D0 (en) 2003-11-14 2003-12-17 Novartis Ag Organic compounds
WO2005094823A1 (ja) 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. Ｆｌｔ－３阻害剤
US7517910B2 (en) * 2004-03-30 2009-04-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives

Also Published As

Publication number Publication date
WO2006033943A3 (en) 2006-06-01
JP5063351B2 (ja) 2012-10-31
US20070293507A1 (en) 2007-12-20
AU2005287170A1 (en) 2006-03-30
AU2005287170B2 (en) 2012-03-29
EP1797072A4 (en) 2009-09-09
EP1797072A2 (en) 2007-06-20
WO2006033943A2 (en) 2006-03-30
JP2012153720A (ja) 2012-08-16
JP2008513464A (ja) 2008-05-01
US8710038B2 (en) 2014-04-29

Similar Documents

Publication Publication Date Title
AU2005287170B2 (en) Pyrazole kinase modulators and methods of use
JP5010917B2 (ja) ｃ−Ｋｉｔ調節因子および使用方法
CA2565200C (en) Raf modulators and methods of use
AU2004230928B2 (en) Tie-2 modulators and methods of use
EP1841760B1 (en) Pyrimidine derivatives as kinase modulators and method of use
AU2005322085B2 (en) [1H-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70S6K, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
US7973061B2 (en) Anaplastic lymphoma kinase modulators and methods of use
WO2004091480A2 (en) Tie-2 modulators and methods of use
EP1678168A2 (en) P70s6 kinase modulators and method of use
US7626031B2 (en) Substituted 3-(diarylmethylene)indolin-2-ones and methods of their use

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150915